{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T08:30:26Z","timestamp":1786437026503,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04538-8","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T08:02:31Z","timestamp":1786435351000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biologically adaptive radiation oncology in oligometastatic and oligoprogressive disease: MR- and CBCT-guided adaptation, molecular imaging, dose painting, biomarkers, and AI"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5441-1306","authenticated-orcid":false,"given":"Hassan","family":"Tariq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8753-3850","authenticated-orcid":false,"given":"Tayyab","family":"Afzal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6983-0493","authenticated-orcid":false,"given":"Abdullah","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"4538_CR1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","volume":"148","author":"Y Lievens","year":"2020","unstructured":"Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol. 2020;148:157\u201366. https:\/\/doi.org\/10.1016\/j.radonc.2020.04.003.","journal-title":"Radiother Oncol"},{"key":"4538_CR2","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","volume":"21","author":"M Guckenberger","year":"2020","unstructured":"Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. Characterisation and classification of oligometastatic disease: an ESTRO and EORTC consensus recommendation. Lancet Oncol. 2020;21:e18\u201328. https:\/\/doi.org\/10.1016\/S1470-2045(19)30718-1.","journal-title":"Lancet Oncol"},{"key":"4538_CR3","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41571-019-0220-6","volume":"16","author":"SP Pitroda","year":"2019","unstructured":"Pitroda SP, Weichselbaum RR. Integrated molecular and clinical staging defines the spectrum of metastatic cancer. Nat Rev Clin Oncol. 2019;16:581\u20138. https:\/\/doi.org\/10.1038\/s41571-019-0220-6.","journal-title":"Nat Rev Clin Oncol"},{"key":"4538_CR4","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","volume":"393","author":"DA Palma","year":"2019","unstructured":"Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised phase 2 trial. Lancet. 2019;393:2051\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(18)32487-5.","journal-title":"Lancet"},{"key":"4538_CR5","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.20.00818","volume":"38","author":"DA Palma","year":"2020","unstructured":"Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol. 2020;38:2830\u20138. https:\/\/doi.org\/10.1200\/JCO.20.00818.","journal-title":"J Clin Oncol"},{"key":"4538_CR6","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1200\/JCO.19.00201","volume":"37","author":"DR Gomez","year":"2019","unstructured":"Gomez DR, Tang C, Zhang J, Blumenschein GR Jr, Hernandez M, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a phase II randomized study. J Clin Oncol. 2019;37:1558\u201365. https:\/\/doi.org\/10.1200\/JCO.19.00201.","journal-title":"J Clin Oncol"},{"key":"4538_CR7","doi-asserted-by":"publisher","first-page":"e173501","DOI":"10.1001\/jamaoncol.2017.3501","volume":"4","author":"P Iyengar","year":"2018","unstructured":"Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2018;4:e173501. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3501.","journal-title":"JAMA Oncol"},{"key":"4538_CR8","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","volume":"36","author":"P Ost","year":"2018","unstructured":"Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective randomized multicenter phase II trial. J Clin Oncol. 2018;36:446\u201353. https:\/\/doi.org\/10.1200\/JCO.2017.75.4853.","journal-title":"J Clin Oncol"},{"key":"4538_CR9","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","volume":"6","author":"R Phillips","year":"2020","unstructured":"Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, et al. Outcomes of observation versus stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020;6:650\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0147.","journal-title":"JAMA Oncol"},{"key":"4538_CR10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","volume":"403","author":"CJ Tsai","year":"2024","unstructured":"Tsai CJ, Yang JT, Shaverdian N, Patel J, Shepherd AF, Eng J, et al. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (CURB): an open-label randomised phase 2 study. Lancet. 2024;403:171\u201382. https:\/\/doi.org\/10.1016\/S0140-6736(23)01857-3.","journal-title":"Lancet"},{"key":"4538_CR11","doi-asserted-by":"publisher","unstructured":"Chmura SJ, Winter KA, Salama JK, Woodward WW, Borges VF, Al-Hallaq H, et al. NRG-BR002: a phase IIR\/III trial of standard-of-care systemic therapy with or without stereotactic body radiotherapy and\/or surgical resection for newly oligometastatic breast cancer. J Clin Oncol. 2022;40(16_suppl):1007. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.1007.","DOI":"10.1200\/JCO.2022.40.16_suppl.1007"},{"key":"4538_CR12","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1118\/1.3438081","volume":"37","author":"SH Benedict","year":"2010","unstructured":"Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010;37:4078\u2013101. https:\/\/doi.org\/10.1118\/1.3438081.","journal-title":"Med Phys"},{"key":"4538_CR13","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.ijrobp.2020.10.021","volume":"109","author":"CK Glide-Hurst","year":"2021","unstructured":"Glide-Hurst CK, Lee P, Yock AD, Olsen JR, Cao M, Siddiqui F, et al. Adaptive radiation therapy strategies and technical considerations: a state of the art review from NRG Oncology. Int J Radiat Oncol Biol Phys. 2021;109:1054\u201375. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.10.021.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4538_CR14","doi-asserted-by":"publisher","first-page":"e636","DOI":"10.1002\/mp.14695","volume":"48","author":"CK Glide-Hurst","year":"2021","unstructured":"Glide-Hurst CK, Paulson ES, McGee K, Tyagi N, Hu Y, Balter J, et al. Task Group 284 report: magnetic resonance imaging simulation in radiotherapy: considerations for clinical implementation, optimization, and quality assurance. Med Phys. 2021;48:e636\u201370. https:\/\/doi.org\/10.1002\/mp.14695.","journal-title":"Med Phys"},{"key":"4538_CR15","doi-asserted-by":"publisher","unstructured":"de Mol van Otterloo SR, Christodouleas JP, Blezer ELA, Akhiat H, Brown K, Choudhury A, et al. Patterns of care, tolerability, and safety of the first cohort treated on a high-field MR-linac within MOMENTUM. Int J Radiat Oncol Biol Phys. 2021;111:867\u2013875. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.07.003.","DOI":"10.1016\/j.ijrobp.2021.07.003"},{"key":"4538_CR16","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.radonc.2017.11.032","volume":"126","author":"L Henke","year":"2018","unstructured":"Henke L, Kashani R, Robinson C, Curcuru A, DeWees T, Bradley J, et al. Phase I trial of stereotactic MR-guided online adaptive radiation therapy for oligometastatic or unresectable primary abdominal malignancies. Radiother Oncol. 2018;126:519\u201326. https:\/\/doi.org\/10.1016\/j.radonc.2017.11.032.","journal-title":"Radiother Oncol"},{"key":"4538_CR17","doi-asserted-by":"publisher","unstructured":"Daamen LA, de Mol van Otterloo SR, van Goor IWJM, Eijkelenkamp H, Erickson BA, Hall WA, et al. Online adaptive MR-guided stereotactic radiotherapy for unresectable upper-abdominal malignancies using a 1.5 T MR-linac. Acta Oncol. 2022;61:111\u2013115. https:\/\/doi.org\/10.1080\/0284186X.2021.2012593.","DOI":"10.1080\/0284186X.2021.2012593"},{"key":"4538_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071636","volume":"13","author":"PB Romesser","year":"2021","unstructured":"Romesser PB, Tyagi N, Crane CH. Magnetic resonance imaging-guided adaptive radiotherapy for colorectal liver metastases. Cancers (Basel). 2021;13:1636. https:\/\/doi.org\/10.3390\/cancers13071636.","journal-title":"Cancers (Basel)"},{"key":"4538_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phro.2020.12.004","volume":"17","author":"P Sibolt","year":"2021","unstructured":"Sibolt P, Andersson LM, Calmels L, Sjostrom D, Bjelkengren U, Geertsen P, et al. Clinical implementation of artificial intelligence-driven cone-beam CT-guided online adaptive radiotherapy in the pelvic region. Phys Imaging Radiat Oncol. 2021;17:1\u20137. https:\/\/doi.org\/10.1016\/j.phro.2020.12.004.","journal-title":"Phys Imaging Radiat Oncol"},{"key":"4538_CR20","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.phro.2022.04.009","volume":"22","author":"LGM Zwart","year":"2022","unstructured":"Zwart LGM, Ong F, Ten Asbroek LA, van Dieren EB, Koch SA, Bhawanie A, et al. Cone-beam CT-guided online adaptive radiotherapy is feasible for prostate cancer patients. Phys Imaging Radiat Oncol. 2022;22:98\u2013103. https:\/\/doi.org\/10.1016\/j.phro.2022.04.009.","journal-title":"Phys Imaging Radiat Oncol"},{"key":"4538_CR21","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective randomized multicentre study. Lancet. 2020;395:1208\u201316. https:\/\/doi.org\/10.1016\/S0140-6736(20)30314-7.","journal-title":"Lancet"},{"key":"4538_CR22","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","volume":"7","author":"TA Hope","year":"2021","unstructured":"Hope TA, Eiber M, Armstrong WR, Juarez R, Murthy V, Lawhn-Heath C, et al. Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection before radical prostatectomy and pelvic lymph-node dissection: a multicentre prospective phase 3 imaging trial. JAMA Oncol. 2021;7:1635\u201342. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3771.","journal-title":"JAMA Oncol"},{"key":"4538_CR23","unstructured":"US Food and Drug Administration. Device classification under section 513 (f)(2): fludeoxyglucose F18-guided radiation therapy system; De Novo number DEN220014. Decision date 1 February 2023."},{"key":"4538_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/acm2.13606","volume":"23","author":"MS Hwang","year":"2022","unstructured":"Hwang MS, Lalonde R, Huq MS. A detailed process map for clinical workflow of a biology-guided radiotherapy machine. J Appl Clin Med Phys. 2022;23:e13606. https:\/\/doi.org\/10.1002\/acm2.13606.","journal-title":"J Appl Clin Med Phys"},{"key":"4538_CR25","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.ijrobp.2023.12.019","volume":"118","author":"LK Vitzthum","year":"2024","unstructured":"Vitzthum LK, Surucu M, Gensheimer MF, Kovalchuk N, Han B, Pham D, et al. BIOGUIDE-X: a first-in-human study of the performance of positron emission tomography-guided radiation therapy. Int J Radiat Oncol Biol Phys. 2024;118:1172\u201380. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.12.019.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4538_CR26","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/S1470-2045(05)01737-7","volume":"6","author":"SM Bentzen","year":"2005","unstructured":"Bentzen SM. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol. 2005;6:112\u20137. https:\/\/doi.org\/10.1016\/S1470-2045(05)01737-7.","journal-title":"Lancet Oncol"},{"key":"4538_CR27","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrclinonc.2017.141","volume":"14","author":"P Lambin","year":"2017","unstructured":"Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, van Timmeren J, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14:749\u201362. https:\/\/doi.org\/10.1038\/nrclinonc.2017.141.","journal-title":"Nat Rev Clin Oncol"},{"key":"4538_CR28","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1148\/radiol.2020191145","volume":"295","author":"A Zwanenburg","year":"2020","unstructured":"Zwanenburg A, Vallieres M, Abdalah MA, Aerts HJWL, Andrearczyk V, Apte A, et al. The Image Biomarker Standardization Initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology. 2020;295:328\u201338. https:\/\/doi.org\/10.1148\/radiol.2020191145.","journal-title":"Radiology"},{"key":"4538_CR29","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","volume":"5","author":"WSME Theelen","year":"2019","unstructured":"Theelen WSME, Peulen HMU, Lalezari F, van der Noort V, de Vries JF, Aerts JGJV, et al. Effect of pembrolizumab after stereotactic body radiotherapy versus pembrolizumab alone on tumour response in advanced non-small-cell lung cancer: PEMBRO-RT. JAMA Oncol. 2019;5:1276\u201382. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1478.","journal-title":"JAMA Oncol"},{"key":"4538_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001001","volume":"8","author":"J Welsh","year":"2020","unstructured":"Welsh J, Menon H, Chen D, Verma V, Tang C, Altan M, et al. Pembrolizumab with or without radiation therapy for metastatic non-small-cell lung cancer: a randomized phase I\/II trial. J Immunother Cancer. 2020;8:e001001. https:\/\/doi.org\/10.1136\/jitc-2020-001001.","journal-title":"J Immunother Cancer"},{"key":"4538_CR31","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04538-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04538-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04538-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T08:02:34Z","timestamp":1786435354000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04538-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":31,"alternative-id":["4538"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04538-8","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"assertion":[{"value":"17 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Hassan Tariq, Tayyab Afzal, and Abdullah Khan declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This review article did not involve any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}